Cosmo Bio Co

Cosmo Bio Co EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Cosmo Bio Co (3386.T) as of Oct 27, 2026 is 7.55 %. In the previous year, Year-over-Year EBITDA Growth was -38.73 % — a change of -119.49% (higher).

EBITDA Growth YoY

7.55 %

YoY

-119.49%

Last updated:

Year-over-Year EBITDA Growth of Cosmo Bio Co is 2025 7.55 % . Year-over-Year EBITDA Growth of Cosmo Bio Co was 2024 -38.73 % . It decreases by -119.49% higher compared to the previous year.

The Cosmo Bio Co EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
69.59 JPY
Jan 1, 2019
23.40 JPY
Jan 1, 2020
85.22 JPY
Jan 1, 2021
39.36 JPY
Jan 1, 2022
-22.14 JPY
Jan 1, 2023
-36.40 JPY
Jan 1, 2024
-38.73 JPY
Jan 1, 2025
7.55 JPY
The Cosmo Bio Co EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
7.55 %-119.49%
-38.73 %+6.41%
-36.40 %+64.41%
-22.14 %-156.24%
39.36 %-53.81%
85.22 %+264.13%
23.40 %-66.37%
69.59 %-224.92%
-55.71 %-147.25%
117.91 %+405.77%
23.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Year-over-Year EBITDA Growth of Cosmo Bio Co is 7.55 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co